High-Dose Cyclophosphamide Without Stem Cell Rescue for the Treatment of Refractory Behcet's Disease

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 2, 2011, Pages 301-304

  Henderson, Charles F ^a   Brodsky, Robert A ^a,b   Jones, Richard J ^a,b   Levine, Stuart M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Behcet's disease; Cyclophosphamide; Vasculitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; INFLIXIMAB; PREDNISONE; SALAZOSULFAPYRIDINE; WARFARIN;

ADULT; APHTHOUS ULCER; ARTHRITIS; ARTICLE; BEHCET DISEASE; BLISTER; CASE REPORT; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM ULCER; DRUG MEGADOSE; ERYTHEMA NODOSUM; FEMALE; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MOUTH ULCER; PANCYTOPENIA; PRIORITY JOURNAL; SKIN NODULE; SKIN ULCER; UVEITIS;

ADULT; BEHCET SYNDROME; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME;

EID: 80755163490     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.12.002     Document Type: Article

References (25)

1. Yazici Y., Yurdakul S., Yazici H. Behcet's syndrome. Curr Rheumatol Rep 2010, 12(6):429-435.
2. Mendoza-Pinto C., Garcia-Carrasco M., Jimenez-Hernandez M., Jimenez Hernandez C., Riebeling-Navarro C., Nava Zavala A., et al. Etiopathogenesis of behcet's disease. Autoimmun Rev 2010, 9(4):241-245.
3. Kallel A., Miladi M.I., Marzouk S., Feki I., Bahloul Z., Mhiri C. Multiple arterial thrombosis in behcet's disease. Rev Med Interne 2010, 31(6):e1-e4.
4. Jamoussi S.K., Chaaba H., Ben Dhaou B., Kochbati S., Boussema F., Cherif O., et al. Venous involvement in Behcet's disease: A series of 28 cases. Tunis Med 2009, 87(12):829-833.
5. Hatemi G., Silman A., Bang D., Bodaghi B., Chamberlain A.M., Gul A., et al. Management of Behcet disease: A systematic literature review for the european league against rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 2009, 68(10):1528-1534.
6. Brodsky RAHigh-dose cyclophosphamide for autoimmunity and alloimmunity. Immunol Res 2010, 47(1-3):179-184.
7. Criteria for diagnosis of Behcet's disease. international study group for behcet's disease. Lancet 1990, 335(8697):1078-1080.
8. O'Neill T.W., Rigby A.S., Silman A.J., Barnes C. Validation of the international study group criteria for Behcet's disease. Br J Rheumatol 1994, 33(2):115-117.
9. Moyo V.M., Smith D., Brodsky I., Crilley P., Jones R.J., Brodsky R.A. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 2002, 100(2):704-706.
10. Tehlirian C.V., Hummers L.K., White B., Brodsky R.A., Wigley F.M. High-dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis 2008, 67(6):775-781.
11. Petri M., Jones R.J., Brodsky R.A. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003, 48(1):166-173.
12. Brodsky R.A., Sensenbrenner L.L., Jones R.J. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood 1996, 87(2):491-494.
13. Kastan M.B., Schlaffer E., Russo J.E., Colvin O.M., Civin C.I., Hilton J. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990, 75(10):1947-1950.
14. Drachman D.B., Adams R.N., Hu R., Jones R.J., Brodsky R.A. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann NY Acad Sci 2008, 1132:305-314.
15. Krishnan C., Kaplin A.I., Brodsky R.A., Drachman D.B., Jones R.J., Pham D.L., et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008, 65(8):1044-1051.
16. Nousari C.H., Brodsky R., Anhalt G.J. Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol 2003, 49(1):148-150.
17. Brodsky R.A., Petri M., Smith B.D., Seifter E.J., Spivak J.L., Styler M., et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998, 129(12):1031-1035.
18. Maurer B., Hensel M., Max R., Fiehn C., Ho A.D., Lorenz H.M. Autologous haematopoietic stem cell transplantation for Behcet's disease with pulmonary involvement: Analysis after 5 years of follow up. Ann Rheum Dis 2006, 65(1):127-129.
19. Rossi G., Moretta A., Locatelli F. Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behcet disease. Blood 2004, 103(2):748-750.
20. Marmont A.M., Gualandi F., Piaggio G., Podesta M., Teresa van Lint M., Bacigalupo A., et al. Allogeneic bone marrow transplantation (BMT) for refractory Behcet's disease with severe CNS involvement. Bone Marrow Transplant 2006, 37(11):1061-1063.
21. De Cata A., Intiso D., Bernal M., Molinaro F., Mazzoccoli G., D'Alessandro V., et al. Prolonged remission of neuro-Behcet disease following autologous transplantation. Int J Immunopathol Pharmacol 2007, 20(1):91-96.
22. Farge D., Labopin M., Tyndall A., Fassas A., Mancardi G.L., Van Laar J., et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: An observational study on 12 years' experience from the European group for blood and marrow transplantation working party on autoimmune diseases. Haematologica 2010, 95(2):284-292.
23. Daikeler T., Hugle T., Farge D., Andolina M., Gualandi F., Baldomero H., et al. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant 2009, 44(1):27-33.
24. Brodsky R.A., Jones R.J. Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: Advantages and disadvantages. Autoimmunity 2008, 41(8):596-600.
25. Brodsky R.A., Chen A.R., Dorr D., Fuchs E.J., Huff C.A., Luznik L., et al. High-dose cyclophosphamide for severe aplastic anemia: Long-term follow-up. Blood 2010, 115(11):2136-2141.